🇺🇸 Naltrexone-Bupropion Combination in United States

FDA authorised Naltrexone-Bupropion Combination on 10 September 2014

Marketing authorisations

FDA — authorised 10 September 2014

  • Application: NDA200063
  • Marketing authorisation holder: NALPROPION
  • Local brand name: CONTRAVE
  • Indication: TABLET, EXTENDED RELEASE — ORAL
  • Status: approved

Read official source →

FDA

  • Status: approved

Naltrexone-Bupropion Combination in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Naltrexone-Bupropion Combination approved in United States?

Yes. FDA authorised it on 10 September 2014; FDA has authorised it.

Who is the marketing authorisation holder for Naltrexone-Bupropion Combination in United States?

NALPROPION holds the US marketing authorisation.